Literature DB >> 10615230

p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation.

M Gentile1, M Bergman Jungeström, K E Olsen, P Söderkvist, S Wingren.   

Abstract

The p53 protein has proven to be central in tumorigenesis by its cell cycle regulatory properties and both gene mutations and protein accumulation have been associated with poor prognosis in breast cancer. The present study was undertaken to investigate the prognostic significance of gene mutations, p53 protein accumulation and of loss of heterozygosity (LOH) at the TP53 locus in young (age < 37 years) breast cancer patients. In total, gene mutations were found in 21 of the 123 patients (17%), LOH in 20 of the 47 informative cases (43%) and protein accumulation in 47 of the 102 available cases (46%). Log rank analysis revealed no significant association between survival and TP53 mutations (in general), p53 protein accumulation or LOH. However, missense mutations localised to the zinc binding domain were significantly (P = 0.0007) associated with poorer prognosis. As indicated in this as well as other studies, p53 protein accumulation is frequently found in young breast cancer patients, but this protein overexpression appears to be of minor significance for survival. Nevertheless, the present report also suggests that specific mutations contribute substantially to tumour aggressiveness.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10615230     DOI: 10.1016/s0959-8049(99)00121-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Mechanism of the promotion of steatotic HepG2 cell apoptosis by cholesterol.

Authors:  Chunyan Zhu; Ping Xie; Fei Zhao; Lingqiang Zhang; Wei An; Yutao Zhan
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice.

Authors:  Danielle C Shing; Maurizio Trubia; Francesco Marchesi; Enrico Radaelli; Elena Belloni; Cinzia Tapinassi; Eugenio Scanziani; Cristina Mecucci; Barbara Crescenzi; Idoya Lahortiga; Maria D Odero; Giuseppe Zardo; Alicja Gruszka; Saverio Minucci; Pier Paolo Di Fiore; Pier Giuseppe Pelicci
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

3.  Study of mutations in p53 tumour suppressor gene in human sporadic breast cancers.

Authors:  Naina Makwane; Alpana Saxena
Journal:  Indian J Clin Biochem       Date:  2009-09-16

4.  Predicting survival in head and neck squamous cell carcinoma from TP53 mutation.

Authors:  David L Masica; Shuli Li; Christopher Douville; Judith Manola; Robert L Ferris; Barbara Burtness; Arlene A Forastiere; Wayne M Koch; Christine H Chung; Rachel Karchin
Journal:  Hum Genet       Date:  2014-08-10       Impact factor: 4.132

5.  gef gene expression in MCF-7 breast cancer cells is associated with a better prognosis and induction of apoptosis by p53-mediated signaling pathway.

Authors:  Houria Boulaiz; Pablo J Alvarez; Jose Prados; Juan Marchal; Consolación Melguizo; Esmeralda Carrillo; Macarena Peran; Fernando Rodríguez; Alberto Ramírez; Raúl Ortíz; Antonia Aránega
Journal:  Int J Mol Sci       Date:  2011-10-31       Impact factor: 5.923

6.  Revisiting the indication for prophylactic contralateral mastectomy in patients with Li-Fraumeni syndrome and breast cancer. Case report

Authors:  Ximena Briceño-Morales; Clara Briceño-Morales; Silvia Inés Guerrero-Macías; Ana María Pedroza-Durán; Raúl Alexis Súarez-Rodríguez
Journal:  Rev Colomb Obstet Ginecol       Date:  2021-09-30

7.  Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers.

Authors:  Brandon-Luke L Seagle; Kevin H Eng; Monica Dandapani; Judy Y Yeh; Kunle Odunsi; Shohreh Shahabi
Journal:  Oncotarget       Date:  2015-07-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.